AADI VS PRDS Stock Comparison

Performance

AADI
10/100

AADI returned -64.24% in the last 12 months. Based on SPY's performance of -13.86%, its performance is below average giving it a score of 10 of 100.

PRDS
10/100

PRDS returned -43.43% in the last 12 months. Based on SPY's performance of -8.72%, its performance is below average giving it a score of 10 of 100.

Technicals

AADI
57/100

AADI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

PRDS
43/100

PRDS receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

AADI
10/100

AADI has missed earnings 9 times in the last 20 quarters.

PRDS
27/100

PRDS has missed earnings 3 times in the last 20 quarters.

Profit

AADI
13/100

Out of the last 20 quarters, AADI has had 2 profitable quarters and has increased their profits year over year on 2 of them.

PRDS
10/100

Out of the last 9 quarters, PRDS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

AADI
39/100

AADI has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

PRDS
44/100

PRDS has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Aadi Bioscience, Inc. Common Stock Summary

Nasdaq / AADI

Healthcare

Biotechnology

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Pardes Biosciences, Inc. Common Stock Summary

Nasdaq / PRDS

Healthcare

Biotechnology

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

Power up your portfolio